Vulvovaginal Candidiasis - Pipeline Insight, 2024

This “Vulvovaginal Candidiasis - Pipeline Insight, 2024,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Vulvovaginal Candidiasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Vulvovaginal Candidiasis Understanding

Vulvovaginal Candidiasis: Overview

Candidiasis is an infection caused by a yeast (a type of fungus) called Candida. Candida normally lives inside the body (in places such as the mouth, throat, gut, and vagina) and on skin without causing any problems. Sometimes Candida can multiply and cause an infection if the environment inside the vagina changes in a way that encourages its growth. Candidiasis in the vagina is commonly called a “vaginal yeast infection.” Other names for this infection are “vaginal candidiasis,” “vulvovaginal candidiasis,” or “candidal vaginitis.” The symptoms of vaginal candidiasis include: Vaginal itching or soreness, pain during sexual intercourse, pain or discomfort when urinating, abnormal vaginal discharge. Although most vaginal candidiasis is mild, some women can develop severe infections involving redness, swelling, and cracks in the wall of the vagina. Vaginal candidiasis is common, though more research is needed to understand how many women are affected. Women who are more likely to get vaginal candidiasis include those who: Are pregnant, use hormonal contraceptives (for example, birth control pills), have diabetes, have a weakened immune system (for example, due to HIV infection or medicines that weaken the immune system, such as steroids and chemotherapy). Healthcare providers usually diagnose vaginal candidiasis by taking a small sample of vaginal discharge to be examined under a microscope in the medical office or sent to a laboratory for a fungal culture. However, a positive fungal culture does not always mean that Candida is causing symptoms because some women can have Candida in the vagina without having any symptoms. Vaginal candidiasis is usually treated with antifungal medicine. For most infections, the treatment is an antifungal medicine applied inside the vagina or a single dose of fluconazole taken by mouth. Other treatments may be needed for infections that are more severe, that don’t get better, or that keep coming back after getting better.

Vulvovaginal Candidiasis- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Vulvovaginal Candidiasis pipeline landscape is provided which includes the disease overview and Vulvovaginal Candidiasis treatment guidelines. The assessment part of the report embraces, in depth Vulvovaginal Candidiasis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Vulvovaginal Candidiasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Vulvovaginal Candidiasis R&D. The therapies under development are focused on novel approaches to treat/improve Vulvovaginal Candidiasis.

Vulvovaginal Candidiasis Emerging Drugs Chapters

This segment of the Vulvovaginal Candidiasis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Vulvovaginal Candidiasis Emerging Drugs

Oteseconazole : Mycovia Pharmaceuticals Oteseconazole (VT-1161) is a novel, investigational oral therapy for the treatment of recurrent vulvovaginal candidiasis (RVVC). Oteseconazole is designed with the goal of having greater selectivity, fewer side effects and improved efficacy as compared with currently available antifungal agents. Oteseconazole received FDA Qualified Infectious Disease Product and Fast-Track designations and, if approved, could be the first FDA-approved treatment for RVVC.Mycovia Pharmaceutical announced the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for oteseconazole, an oral antifungal product for the treatment of recurrent vulvovaginal candidiasis (RVVC).

MAT2203: Matinas Bio Pharma MAT2203 is an oral and non-toxic encochleated form of amphotericin B (CAmB). This antifungal drug is the primary broad-spectrum treatment for immunocompromised patients. Unlike some other therapies, it doesn’t simply stop fungus from growing, but kills it entirely. The drug is currently in phase 2 stage of development for the treatment ofVulvovaginalCandidiasis.

Benzydamine/econazole : Angelini Pharmaceuticals Angelini Pharmaceuticals is developing an antimycotic vaginal pessary combination comprising benzydamine hydrochloride 6mg and econazole nitrate 150mg in the Treatment of uncomplicated vulvovaginal Candidiasis. To assess the microbiological and clinical efficacy, the safety and acceptability of the benzydamine HCl 6 mg and econazole nitrate 150 mg vaginal pessary, in comparison to Pevaryl® 150 mg vaginal pessary, in the treatment of uncomplicated VVC.Currently, the drug is in Phase 3 stage of development for the treatment of Vulvovaginal Candidiasis.

Miconazole/Domiphen Bromide: Hyloris Pharmaceuticals MCZ-DB is a locally applied vaginal cream, and based on promising results from preclinical studies, it is believed that it could have significant potential in recurring VVC infections, an underserved condition for which there are no locally administered topical therapies currently available. Miconazole-Domiphen Bromide is being developed in Phase 2 stage of development, in partnership with Purna Female Health (PFH).

Vulvovaginal Candidiasis: Therapeutic Assessment

This segment of the report provides insights about the different Vulvovaginal Candidiasis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Vulvovaginal Candidiasis

There are approx. 7+ key companies which are developing the therapies for Vulvovaginal Candidiasis. The companies which have their Vulvovaginal Candidiasis drug candidates in the most advanced stage, i.e. Pre-Registration include, Mycovia Pharmaceuticals.

Phases

This report covers around 7+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Vulvovaginal Candidiasis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Vulvovaginal Candidiasis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Vulvovaginal Candidiasis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Vulvovaginal Candidiasis drugs.

Vulvovaginal Candidiasis Report Insights

• Vulvovaginal Candidiasis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Vulvovaginal Candidiasis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Vulvovaginal Candidiasis drugs?
• How many Vulvovaginal Candidiasis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Vulvovaginal Candidiasis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Vulvovaginal Candidiasis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vulvovaginal Candidiasis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Mycovia Pharmaceuticals
• Matinas BioPharma
• Nova DigmTherapeutics
• Toltec Pharmaceuticals
• LTN Pharm
• ProFem
• Ferrer
• Mariposa Health

Key Products

• Oteseconazole
• MAT2203
• NDV 3
• Benzydamine/econazole
• Miconazole/Domiphen Bromide
• TOL 463

This product will be delivered within 2 business days.